Published in Cancer Res on July 15, 1994
Evolution of p53 in hypoxia-stressed Spalax mimics human tumor mutation. Proc Natl Acad Sci U S A (2004) 1.41
Alterations of p16-pRb pathway and chromosome locus 9p21-22 in sporadic invasive breast carcinomas. Mol Med (1998) 1.06
p53 mutations and expression in breast carcinoma in situ. Am J Pathol (2000) 0.99
Microsatellite instability in early sporadic breast cancer. Br J Cancer (1996) 0.95
Microsatellite instability and loss of heterozygosity in gastric carcinoma in comparison to family history. Am J Pathol (1998) 0.93
Replication error phenotype and p53 gene mutation in lymphomas of mucosa-associated lymphoid tissue. Am J Pathol (1996) 0.92
Immunofluorometric analysis of p53 protein and prostate-specific antigen in breast tumours and their association with other prognostic indicators. Br J Cancer (1995) 0.83
Identification of tumour-associated and germ line p53 mutations in canine mammary cancer. Br J Cancer (1999) 0.80
Screening for TP53 mutations in patients and tumours from 109 Swedish breast cancer families. Br J Cancer (1997) 0.80
Hspb1 and Tp53 Mutation and Expression Analysis in Cat Mammary Tumors. Iran J Biotechnol (2016) 0.75
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol (1998) 8.40
IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood (1997) 4.97
Direct mutagenesis of Ha-ras-1 oncogenes by N-nitroso-N-methylurea during initiation of mammary carcinogenesis in rats. Nature (1985) 4.40
Induction of mammary carcinomas in rats by nitroso-methylurea involves malignant activation of H-ras-1 locus by single point mutations. Nature (1984) 4.38
IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol (1997) 4.32
Compromised HOXA5 function can limit p53 expression in human breast tumours. Nature (2000) 3.78
High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. Proc Natl Acad Sci U S A (2000) 2.70
Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol (1998) 2.57
Molecular links between obesity and breast cancer. Endocr Relat Cancer (2006) 2.44
HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs. Oncogene (2011) 2.42
Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol (2000) 2.38
Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol (1999) 2.36
RNA editing in the Wilms' tumor susceptibility gene, WT1. Genes Dev (1994) 2.17
Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet (2001) 2.16
Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. Cancer Res (2001) 1.95
Activation of methionine synthase by insulin-like growth factor-1 and dopamine: a target for neurodevelopmental toxins and thimerosal. Mol Psychiatry (2004) 1.92
Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol (1999) 1.91
Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer. Oncogene (2001) 1.89
Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol (1999) 1.87
Cytokines, chemokines and growth factors in endometrium related to implantation. Hum Reprod Update (2005) 1.86
Combining serial analysis of gene expression and array technologies to identify genes differentially expressed in breast cancer. Cancer Res (1999) 1.74
Wilms' tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation. Cancer Res (2001) 1.73
Activation of ras oncogenes preceding the onset of neoplasia. Science (1990) 1.68
Mutations in p53 as potential molecular markers for human breast cancer. Proc Natl Acad Sci U S A (1991) 1.65
Improving the standard of operation notes in orthopaedic and trauma surgery: the value of a proforma. Injury (2004) 1.54
Cadmium-Sulfide Crystallites in Cd-(gammaEC)(n)G Peptide Complexes from Tomato. Plant Physiol (1992) 1.44
Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor beta2 promoter in breast cancer cells. Oncogene (2000) 1.40
Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol (1999) 1.37
A single mutation is responsible for the high prevalence of G6PD deficiency in the Vataliya Prajapatis--an endogamous caste group from Western India. Am J Hematol (2001) 1.37
Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol (1999) 1.36
HOXA5 regulates expression of the progesterone receptor. J Biol Chem (2000) 1.28
Intrauterine fetal transfusion, 1965-1976, with an assessment of the surviving children. Am J Obstet Gynecol (1978) 1.22
Influence of ampicillin elimination half-life on in-vitro bactericidal effect. J Antimicrob Chemother (1985) 1.22
Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med (2000) 1.22
Improved detection of mutations in the p53 gene in human tumors as single-stranded conformation polymorphs and double-stranded heteroduplex DNA. PCR Methods Appl (1992) 1.17
Muscle thickness, measured with ultrasound, may be an indicator of lean tissue wasting in multiple organ failure in the presence of edema. Am J Clin Nutr (1995) 1.16
Medical students' self-assessment accuracy in communication skills. Acad Med (1997) 1.15
Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol (1999) 1.14
Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit Rev Oncol Hematol (2001) 1.14
Methylation is less abundant in BRCA1-associated compared with sporadic breast cancer. Ann Oncol (2008) 1.12
Telomerase activity: a marker to distinguish follicular thyroid adenoma from carcinoma. Cancer Res (1997) 1.05
HOXA1-stimulated oncogenicity is mediated by selective upregulation of components of the p44/42 MAP kinase pathway in human mammary carcinoma cells. Oncogene (2007) 1.05
Mimicking the events of menstruation in the murine uterus. Biol Reprod (2003) 1.05
Specific activation of the cellular Harvey-ras oncogene in dimethylbenzanthracene-induced mouse mammary tumors. Mol Cell Biol (1986) 1.03
Activation of H-ras oncogenes in preneoplastic mouse mammary tissues. Oncogene (1990) 1.02
Effect of allopurinol on the pharmacokinetics of 6-mercaptopurine (NSC 755) in cancer patients. Cancer Res (1972) 1.01
High telomerase reverse transcriptase (hTERT) messenger RNA level correlates with tumor recurrence in patients with favorable histology Wilms' tumor. Cancer Res (1999) 1.00
Rituximab: the first monoclonal antibody approved for the treatment of lymphoma. Curr Pharm Biotechnol (2000) 1.00
Telomerase activity as a measure for monitoring radiocurability of tumor cells. FASEB J (1999) 1.00
Human telomerase reverse transcriptase (hTERT) gene expression in thyroid neoplasms. Clin Cancer Res (1999) 1.00
Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity. Ann Oncol (1999) 0.99
Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody. Clin Cancer Res (1999) 0.99
Clinical status and optimal use of rituximab for B-cell lymphomas. Oncology (Williston Park) (1998) 0.98
Minor salivary gland hyalinisation and amyloidosis in low-grade lymphoma of MALT. J Oral Pathol Med (1998) 0.98
Down-regulation of the desmosomal cadherin desmocollin 3 in human breast cancer. Int J Oncol (2001) 0.96
A rodent model for Wilms tumors: embryonal kidney neoplasms induced by N-nitroso-N'-methylurea. Proc Natl Acad Sci U S A (1994) 0.95
A transforming ras gene in tumorigenic guinea pig cell lines initiated by diverse chemical carcinogens. Science (1984) 0.95
Molecular cloning of rat Wilms' tumor complementary DNA and a study of messenger RNA expression in the urogenital system and the brain. Cancer Res (1992) 0.94
Activated K-ras and N-ras oncogenes in primary renal mesenchymal tumors induced in F344 rats by methyl(methoxymethyl)nitrosamine. Mol Cell Biol (1986) 0.94
Telomerase activity in ductal carcinoma in situ and invasive breast cancer. Oncogene (1999) 0.94
Bacterial flora of the cervix during pregnancy. Obstet Gynecol (1968) 0.93
ras oncogenes in chemical carcinogenesis. Curr Top Microbiol Immunol (1989) 0.91
High prevalence of G6PD deficiency in Vataliya Prajapati community in western India. Haematologia (Budap) (2001) 0.91
A new model of dual interacting ligand binding sites on integrin alphaIIbbeta3. J Biol Chem (1999) 0.90
Tubal sterilization. A 15 year survey. Am J Obstet Gynecol (1966) 0.90
CpG methylation as a basis for breast tumor-specific loss of NES1/kallikrein 10 expression. Cancer Res (2001) 0.88
Role of radiation dosimetry in radioimmunotherapy planning and treatment dosing. Crit Rev Oncol Hematol (2001) 0.87
Transforming c-Ki-ras mutation is a preneoplastic event in mouse mammary carcinogenesis induced in vitro by N-methyl-N-nitrosourea. Mol Cell Biol (1990) 0.87
Role of chemical and cytologic analysis of amniotic fluid in determination of fetal maturity. Am J Obstet Gynecol (1969) 0.87
Soluble antigen therapy induces apoptosis of autoreactive T cells preferentially in the target organ rather than in the peripheral lymphoid organs. Eur J Immunol (1998) 0.87
Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a. Clin Cancer Res (2000) 0.87
Applications of telomerase research in the fight against cancer. Mol Med Today (1999) 0.85
Rapid entry and downregulation of T cells in the central nervous system during the reinduction of experimental autoimmune encephalomyelitis. J Neuroimmunol (2001) 0.85
Careful histological confirmation and microdissection reveal telomerase activity in otherwise telomerase-negative breast cancers. Clin Cancer Res (1998) 0.85
Differential effects of Wilms tumor WT1 splice variants on the insulin receptor promoter. Biochem Mol Med (1997) 0.84
-Hemolytic streptococcus infections in postpartum patients. Obstet Gynecol (1973) 0.83
Mechanisms of the dose-dependent kinetics of trichloroethylene: oral bolus dosing of rats. Toxicol Appl Pharmacol (2000) 0.83
The isolation, purification and some properties of pheromaxein, the pheromonal steroid-binding protein, in porcine submaxillary glands and saliva. J Endocrinol (1988) 0.83
Ulcerating enteritis associated with flucytosine therapy. Gastroenterology (1982) 0.83
Altered WAF1 genes do not play a role in abnormal cell cycle regulation in breast cancers lacking p53 mutations. Clin Cancer Res (1997) 0.82
Telomerase activity and prognosis in primary breast cancers. J Clin Oncol (1999) 0.82
Crystal structure of the coat protein from the GA bacteriophage: model of the unassembled dimer. Protein Sci (1996) 0.82
Donate organs not malignancies: postoperative small cell lung carcinoma in a marginal living kidney donor. Transplant Proc (2007) 0.82
Rho (D) immune prophylaxis. A double-blind cooperative study. Obstet Gynecol (1970) 0.82
Two monoclonal antibodies selective for human mammary carcinoma. Cancer Res (1985) 0.82
Altered placental development in interleukin-10 null mutant mice. Placenta (2003) 0.82
Study of antiviral activity of tender leaves of Margosa tree (Melia azadericta) on vaccinia and variola virus: a preliminary report. Indian J Med Res (1969) 0.82
Telomerase activity in the differential diagnosis of papillary carcinoma of the thyroid. Surgery (1997) 0.82
Molecular cloning and chromosomal localization of Chinese hamster telomeric protein chTRF1. Its potential role in chromosomal instability. Oncogene (1998) 0.82
Monoclonal antibodies: a new era in the treatment of non-Hodgkin's lymphoma. Curr Pharm Biotechnol (2001) 0.81
Obstetric malpresentations: twenty years' experience. Am J Obstet Gynecol (1973) 0.81
Multistage prostate carcinogenesis: the role of hormones. Princess Takamatsu Symp (1991) 0.81
An isoform of the Wilms' tumor suppressor gene potentiates granulocytic differentiation. Leukemia (2003) 0.81
Flexible sigmoidoscopy does not significantly increase polyp and cancer detection yield when used to supplement CT colonography. Digestion (2011) 0.81
Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy. Ann Oncol (2001) 0.81
Amniotic fluid lecithin-sphingomyelin ratio as a measure of fetal pulmonary maturity. J Iowa Med Soc (1972) 0.80
Dendritic-NK cell interactions in P. gingivalis-specific responses. J Dent Res (2005) 0.80
Quantitative analysis of myocardial perfusion changes with transmyocardial laser revascularization. Am J Cardiol (2001) 0.80
Effect of concurrent sucralfate administration on the absorption of erythromycin. J Clin Pharmacol (1990) 0.79